Coeptis Therapeutics Holdings, Inc.

Healthcare · Biotechnology · United States

Last price 16.4 USD (Apr 24, 2026, 4:00 PM EDT) · Market cap 102.06M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, operates as a biopharmaceutical and technology company. The company is developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its therapeutic portfolio includes an allogeneic cellular immunotherapy platform; and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. The company’s product pipeline consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic l...